Project Grant R21DA029787

The National Institute on Drug Abuse (NIDA) awarded the University of Texas Health Science Center at Houston $2,085,384 on June 15, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a pilot mechanistic study investigating semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), as a potential treatment for cocaine use disorder (CUD). This R01 Stage IIA project, which will conclude February 28, 2029, will generate proof-of-concept evidence demonstrating...

Federal Cooperative Agreement Summary The University of Texas Health Science Center at Houston received a $6.24 million Cooperative Agreement from the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a clinical research study evaluating a novel treatment combination for cocaine use disorder (CUD). The award, dated September 15, 2025, with a completion date of June 30, 2029, supports research pairing contingency management (CM)—a...

The University of Pennsylvania received a $527,837 Project Grant award from the National Institute on Drug Abuse, part of the Department of Health and Human Services, to study altered midbrain GABAergic circuitry and its role in driving greater cocaine self-administration. Specifically, the researchers will characterize the functional state of midbrain GABAergic circuitry and the disposition of the KCC2 potassium-chloride cotransporter during cocaine self-administration, extinction, and...

Iontx Inc. received a $400,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop novel pharmacological treatments for cocaine use disorder (CUD). The award, issued on May 15, 2025, with a completion date of April 30, 2026, supports the optimization and preclinical evaluation of a first-in-class small-molecule modulator targeting the FGF13 (fibroblast growth factor 13) and NAV1.6 (voltage-gated sodium...

Summary of Federal Cooperative Agreement Award Virginia Commonwealth University received a $643,019 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a proof-of-concept randomized controlled trial evaluating psilocybin-assisted treatment for cocaine use disorder (CocUD). The award, effective July 15, 2025, through June 30, 2027, supports research combining psilocybin with psychedelic...

Federal Grant Award Summary Wake Forest University Health Sciences received a $474,347 Project Grant from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) beginning August 15, 2025, with completion scheduled for April 30, 2030. The award supports research investigating the impact of nicotine and alcohol co-use on cocaine abuse potential using cynomolgus monkey models. The research directly addresses a critical public health gap, as...

Federal Cooperative Agreement Summary The National Institute on Drug Abuse awarded a Cooperative Agreement totaling $790,937 under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Research Foundation for the State University of New York, effective August 1, 2025, through April 30, 2030. This award supports research investigating the genetic substrates underlying cue-reactivity and cocaine motivation to advance understanding of the biological mechanisms contributing to the...

The National Institute on Drug Abuse (NIDA) awarded $795,090 to the University of Texas Medical Branch at Galveston under the Drug Use and Addiction Research Programs (CFDA 93.279) Project Grant mechanism, effective September 1, 2025, through May 31, 2030. This research initiative focuses on the discovery and development of G protein-coupled receptor 52 (GPR52) ligand probes as novel therapeutic targets for cocaine use disorder (CUD). The project employs an informatics-driven approach to...

Federal Grant Award Summary Award Details: The National Institute on Drug Abuse (NIDA) awarded $877,500 to the University of California, San Diego under the Drug Use and Addiction Research Programs (CFDA 93.279) Project Grant mechanism on July 15, 2025, with a completion date of June 30, 2027. Research Deliverables: This project delivers basic research investigating the neurobiological mechanisms underlying cocaine use disorder (CUD) susceptibility through a novel predictive methodology called...

This $149,284 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to Vanderbilt University will fund research to understand how chronic cocaine use disrupts the neural processing of aversive, non-drug stimuli in the brain. The study aims to define the precise temporal parameters under which dopamine release modulates the activity of genetically-defined neuron populations in the nucleus accumbens, both at baseline and in...